Hunter's Health Hacks
Posts
Retatrutide By The Numbers

Retatrutide By The Numbers

Data we have so far

Hunter Williams
January 31, 2025

You’ve probably heard about Retatrutide by now.

In my opinion, it’s the most extraordinary peptide we have access to in the research world at this moment in time.

However, even among peptide users, so few people have tried it or substituted it in place of their semaglutide or tirzepatide.

In the spirit of education, today, I want to look at Retatrutide by the numbers.

I also highly recommend Jay’s most recent article, as well as the video we filmed yesterday.

(we also just restocked retatrutide at BioLongevity Labs, use HUNTER10 for 10% off)

How Retatrutide Works

Retatrutide is a triple hormone receptor agonist, meaning it activates three key metabolic pathways:

GLP-1 receptor (like semaglutide and tirzepatide) – reduces appetite, slows gastric emptying, and improves insulin sensitivity.
GIP receptor (also targeted by tirzepatide) – enhances insulin release and has potential anabolic effects on muscle tissue.
Glucagon receptor – increases energy expenditure and promotes fat oxidation.

This unique combination means retatrutide doesn’t just suppress appetite; it also boosts metabolism and increases fat burning, making it one of the most potent weight-loss peptides studied to date.

Retatrutide vs. Tirzepatide and Semaglutide

Clinical data shows that retatrutide is outperforming both tirzepatide and semaglutide in key areas of weight loss and metabolic health:

Obesity Trial (48 weeks, non-diabetic participants)
- 17.5% weight loss at 24 weeks (12 mg dose) vs. ~15% with tirzepatide and ~12% with semaglutide
- 24.2% weight loss at 48 weeks (12 mg dose) – unmatched by any other peptide in trials
- 83% of participants lost at least 15% of their body weight
Liver Fat Reduction Study (NAFLD participants)
- 85% of participants saw normal liver fat levels restored after 24-48 weeks (12 mg dose)
Type 2 Diabetes Trial (36 weeks)
- 82% of participants reached HbA1c levels under 6.5%
- Up to 17% weight loss in higher-dose groups

Safety and Side Effects

Like other GLP-1/GIP-based peptides, the main side effects of retatrutide are gastrointestinal (nausea, diarrhea, vomiting)—especially during the early stages of treatment.

However, clinical trials indicate these effects are generally mild to moderate and tend to improve over time as the body adjusts.

I have also personally noticed reta has far fewer side effects than tirz or sema.

Overall, no significant safety concerns have been reported so far.

Final Thoughts

Retatrutide is shaping up to be one of the most powerful weight-loss and metabolic health peptides yet.

If it progresses through clinical trials successfully, it could represent a new standard in treating obesity and metabolic disorders.

Of course, we’ll have to wait and see how it performs in long-term studies, but the early data is incredibly promising.